LVW Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

LVW Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-582	Closed	-$231K	–	440
2025 Q4	$231K	Sell	582 -8	-1%	-$3.54K	0.02%	316
2025 Q3	$269K	Buy	+590	New	+$240K	0.03%	291

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LVW Advisors's ALNY Position: Q1 2026 in Review

LVW Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 582 shares — an estimated $231K sold.

LVW Advisors first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $269K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

LVW Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
LVW Advisors sold 582 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $231K.
LVW Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
LVW Advisors's Alnylam Pharmaceuticals position peaked at $269K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on LVW Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.